Cosunter(SZ:300436) Zheng Quan Zhi Xing·2025-05-23 13:14Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. was established as a joint-stock company from the transformation of Fujian Guangshentang Pharmaceutical Co., Ltd. [1] - The company is located in Fujian Province, with its registered capital and paid-in capital both amounting to 159.267 million RMB as of December 31, 2024 [3]. Business Nature and Activities - The company operates in the pharmaceutical manufacturing industry, with a business scope that includes drug production, wholesale, retail, food sales, health food production, and drug import/export [3]. - The company has 13 subsidiaries included in its consolidated financial statements, with an increase of 2 subsidiaries compared to the previous period [3]. Financial Reporting - The financial statements were approved by the board of directors on April 16, 2025 [4]. - The company prepares its financial statements based on actual transactions and events, adhering to the accounting standards set by the Ministry of Finance [4]. Financial Condition - The company has experienced continuous losses over the past three years due to significant R&D investments, with a consolidated asset-liability ratio of 72.42% as of December 31, 2024 [4]. - The company has a total of 300 million RMB in borrowings, with available cash of 143 million RMB and unused credit lines of 125 million RMB, indicating a strategy to maintain liquidity [4]. Capital Structure - The company issued 17.5 million A-shares in 2015, with 3.5 million shares being transferred and 14 million new shares issued [1]. - In 2021, the company issued 18.777 million shares to specific investors, with the new shares listed on July 9, 2021 [1]. Stock Option Plan - The company approved a stock option incentive plan, allowing 22 eligible participants to exercise 798,000 stock options at a price of 31.23 RMB per share, with a total exercise amount of approximately 15.3 million RMB [2].